贺益盛

校长青年学者

助理教授

教育背景

博士 (香港中文大学)
学士 (中国药科大学）
 

研究领域
药物安全、药物代谢动力学、环境化合物毒理、分子标志物、分子流行病学、肝肠轴
电子邮件
heyisheng@cuhk.edu.cn
个人简介

贺益盛教授于中国药科大学获得本科学位，并于2018年获香港中文大学博士学位。此后在香港中文大学生物医学院进行博士后研究，并在2021年10月成为本校研究助理教授。

贺教授于2022年9月加入香港中文大学（深圳）医学院担任助理教授，其研究方向为药物安全，尤其是药物致肝损伤的预防、诊断及治疗。针对药物致肝损伤临床诊断手段缺失的问题，贺教授致力于开发基于药物分子致毒机制的特异生物标志物，用以精准诊断药物引起的急、慢性肝损伤。针对药物致肝损伤的治疗手段有限且预后欠佳的问题，贺教授致力于阐明基于代谢激活的药物致毒模式，聚焦药物致肝损伤的细胞分子病理机制，并开发基于病因的治疗方案。此外，针对天然产物致肝损伤的问题，贺教授利用体内药代动力学结合体外吸收代谢及致毒模型，探究个性化肝损伤风险评估的标准。

贺教授从事研究：1. 药物致肝损伤；2. 药代动力学及毒代动力学；3. 生物标志物开发及转化应用；4. 分子毒理。贺教授以第一作者在毒理、药理及肝病学期刊Hepatology, Acta Pharmaceutica Sinica B, Archives of Toxicology, Environmental Science & Technology Letters, Journal of Hazardous Materials发表研究性论文，担任iMeta, Chinese Medicine, eGastroenterology, Frontiers in Pharmacology, Scientific Reports, Future Integrative Medicine期刊编辑或青年编委，入选国家级海外引才项目，并主持国家、省、市多项自然科学基金项目。

学术著作

  1. To YC, Pan Y, Yan X, He Y#, and Lin G#. The toxicokinetic and metabolism of structurally diverse pyrrolizidine alkaloids in rats. Journal of Ethnopharmacology, 2024 Jan 1; 321:117390. (#Co-corresponding authors)
  2. Wu X, Huang H, Li M, Wanga Y, Wu X, Wang Q, Shen J, Xiao Z, Zhao Y, Du F, Chen Y, Yang Y, Zhao Q, Zeng J, He Y#, and Xiao J#. Excessive consumption of the sugar rich longan fruit promoted the development of nonalcoholic fatty liver disease via mediating gut dysbiosis. Food Frontiers, 2023 Dec 13; 4: 491–510. (#Co-corresponding authors)
  3. He Y, Long Y, Zhang C, Ma J, Ke C, Tang C, Ye Y, and Lin G. Dietary alcohol exacerbates the hepatotoxicity induced by pyrrolizidine alkaloids: Hazard from food contamination. Journal of Hazardous Materials, 2022 Feb 15;424:127706.
  4. Zhu L, Xue J, He Y, Xia Q, Fu PP, Lin G. Correlation Investigation between Pyrrole-DNA and Pyrrole-Protein Adducts in Male ICR Mice Exposed to Retrorsine, a Hepatotoxic Pyrrolizidine Alkaloid. Toxins. 2022 May 28;14(6):377.
  5. Wang Z, Ma J, He Y, Miu KK, Yao S, Tang C, Ye Y, Lin G. Nrf2-mediated liver protection by 18β-glycyrrhetinic acid against pyrrolizidine alkaloid-induced toxicity through PI3K/Akt/GSK3β pathway. Phytomedicine. 2022 May 13:154162.
  6. Wang Z, Ma J, Yao S, He Y, Miu KK, Xia Q, Fu PP, Ye Y, Lin G. Liquorice extract and 18β-glycyrrhetinic acid protect against experimental pyrrolizidine alkaloid-induced hepatotoxicity in rats through inhibiting cytochrome P450-mediated metabolic activation. Frontiers in pharmacology. 2022;13.
  7. Xiao Y, Yi H, Wang G, Chen S, Li X, Wu Q, Zhang S, Deng K, He Y#, Yang X#. Electrochemiluminescence sensor for point-of-care detection of pyrrolizidine alkaloids. Talanta. 2022 Jun 1:123645. (#Co-corresponding authors)
  8. Ma J, Zhang C, He Y, Chen X, Lin G. Fasting augments pyrrolizidine alkaloid-induced hepatotoxicity. Archives of Toxicology. 2022 Feb;96(2):639-51.
  9. He Y*, Shi M*, Wu X, Ma J, Ng KT, Xia Q, Zhu L, Fu PP, Man K, Tsui SK, Lin G. Mutational signature analysis reveals widespread contribution of pyrrolizidine alkaloid exposure to human liver cancer. Hepatology. 2021 Jul;74(1):264-80. (*Co-first authors)
  10. He Y*, Ma J*, Fan X, Ding L, Ding X, Zhang QY, Lin G. The key role of gut–liver axis in pyrrolizidine alkaloid-induced hepatotoxicity and enterotoxicity. Acta Pharmaceutica Sinica B. 2021 Dec 1;11(12):3820-35. (*Co-first authors)
  11. He Y*, Zhang W*, Ma J*, Xia Q, Song Z, Zhu L, Zhang C, Liu J, Ye Y, Fu PP, Zhuge Y. Blood pyrrole–DNA adducts define the early tumorigenic risk in patients with pyrrolizidine alkaloid-induced liver injury. Environmental Science & Technology Letters. 2021 Jun 15;8(7):551-7. (*Co-first authors)
  12. Zhu L, Zhang C, Zhang W, Xia Q, Ma J, He X, He Y, Fu PP, Jia W, Zhuge Y, Lin G. Developing urinary pyrrole–amino acid adducts as non-invasive biomarkers for identifying pyrrolizidine alkaloids-induced liver injury in human. Archives of Toxicology. 2021 Oct;95(10):3191-204.
  13. Chen X, Ma J, He Y, Xue J, Song Z, Xu Q, Lin G. Characterization of liver injury induced by a pyrrolizidine alkaloid in rats. Phytomedicine. 2021 Aug 1;89:153595.
  14. He Y*, Zhu L*, Ma J, Lin G. Metabolism-mediated cytotoxicity and genotoxicity of pyrrolizidine alkaloids. Archives of Toxicology. 2021 Jun;95(6):1917-42. (*Co-first authors)
  15. Huang H, Li M, Wang Y, Wu X, Shen J, Xiao Z, Zhao Y, Du F, Chen Y, Wu Z, Ji H, Zhang C, Li J, Wen Q, Kaboli PJ, Cho CH, Wang S, Wang Y, He Y#, Wu X#. Excessive intake of longan arillus alters gut homeostasis and aggravates colitis in mice. Frontiers in pharmacology. 2021 Mar 26;12:640417. (#Co-corresponding authors)
  16. Ma J*, Zhang W*, He Y*, Zhu L, Zhang C, Liu J, Ye Y, Zhuge Y, Lin G. Clinical application of pyrrole–hemoglobin adducts as a biomarker of pyrrolizidine alkaloid exposure in humans. Archives of Toxicology. 2021 Feb;95(2):759-65. (*Co-first authors)
  17. He Y*, Lian W*, Ding L, Fan X, Ma J, Zhang QY, Ding X, Lin G. Lung injury induced by pyrrolizidine alkaloids depends on metabolism by hepatic cytochrome P450s and blood transport of reactive metabolites. Archives of toxicology. 2021 Jan;95(1):103-16. (*Co-first authors)
  18. Zhu H, He Y, Ma J, Zhou J, Kong M, Wu CY, Mao Q, Lin G, Li SL. The dual roles of ginsenosides in improving the anti-tumor efficiency of cyclophosphamide in mammary carcinoma mice. Journal of Ethnopharmacology. 2021 Jan 30;265:113271.
  19. He Y, Zhu L, Ma J, Wong L, Zhao Z, Ye Y, Fu PP, Lin G. Comprehensive investigation and risk study on pyrrolizidine alkaloid contamination in Chinese retail honey. Environmental Pollution. 2020 Dec 1;267:115542.
  20. Song Z*, He Y*, Ma J, Fu PP, Lin G. Pulmonary toxicity is a common phenomenon of toxic pyrrolizidine alkaloids. Journal of Environmental Science and Health, Part C. 2020 Apr 2;38(2):124-40. (*Co-first authors)
  21. Zhu L, Wang Z, Wong L, He Y, Zhao Z, Ye Y, Fu PP, Lin G. Contamination of hepatotoxic pyrrolizidine alkaloids in retail honey in China. Food Control. 2018 Mar 1;85:484-94.
  22. He Y, Sun W, Zhang BY, Xu LH, Yang J, Gao W, Qi LW, Li P, Wen XD. Application of a sensitive liquid chromatography-mass spectrometry method to a pharmacokinetic study of nerolidol in rat plasma. Analytical Methods. 2016;8(4):785-9.
  23. Sun W, He Y, Xu LH, Zhang BY, Qi LW, Yang J, Li P, Wen XD. Pharmacokinetic profiles of falcarindiol and oplopandiol in rats after oral administration of polyynes extract of Oplopanax elatus. Chinese Journal of Natural Medicines. 2016 Sep 1;14(9):714-20.
  24. He Y, Sun W, Wang CZ, Qi LW, Yang J, Li P, Wen XD, Yuan CS. Effects of American ginseng on pharmacokinetics of 5‐fluorouracil in rats. Biomedical Chromatography. 2015 May;29(5):762-7.
  25. Ma J, Zheng L, He Y, Li HJ. Hepatotoxic assessment of Polygoni Multiflori Radix extract and toxicokinetic study of stilbene glucoside and anthraquinones in rats. Journal of Ethnopharmacology. 2015 Mar 13;162:61-8.
  26. Li Y, Li JJ, Wen XD, Pan R, He Y, Yang J. Metabonomic analysis of the therapeutic effect of Potentilla discolor in the treatment of type 2 diabetes mellitus. Molecular bioSystems. 2014;10(11):2898-906.
  27. Ma J, Zheng L, Deng T, Li CL, He Y, Li HJ, Li P. Stilbene glucoside inhibits the glucuronidation of emodin in rats through the down-regulation of UDP-glucuronosyltransferases 1A8: application to a drug–drug interaction study in Radix Polygoni Multiflori. Journal of Ethnopharmacology. 2013 May 20;147(2):335-40.
  28. Zhou H, Bian D, Jiao X, Wei Z, Zhang H, Xia Y, He Y, Dai Y. Paeoniflorin protects against lipopolysaccharide-induced acute lung injury in mice by alleviating inflammatory cell infiltration and microvascular permeability. Inflammation Research. 2011 Oct;60(10):981-90.